⚡️🇺🇸#CVS #отчетность
CVS Health Q3 Non-GAAP
- EPS of $1.66 beats by $0.32; GAAP EPS of $0.93 beats by $0.01.
-Revenue of $67.1B (+3.5% Y/Y) beats by $560M.
-PBM revenue of $35.7B vs. $35.15B, retail revenue of $22.7B vs. $22.26B and health care benefits revenue of $18.7B vs. $18.53B.
FY20 Guidance:
-EPS of $7.35-$7.45 from prior guidance of $7.14-$7.27 vs. $7.23.
-Raised GAAP diluted EPS guidance range to $5.60 to $5.70 from $5.16 to $5.29
-Raised cash flow from operations guidance range to $12.75 billion to $13.25 billion from $11.0 billion to $11.5 billion
CVS Health Q3 Non-GAAP
- EPS of $1.66 beats by $0.32; GAAP EPS of $0.93 beats by $0.01.
-Revenue of $67.1B (+3.5% Y/Y) beats by $560M.
-PBM revenue of $35.7B vs. $35.15B, retail revenue of $22.7B vs. $22.26B and health care benefits revenue of $18.7B vs. $18.53B.
FY20 Guidance:
-EPS of $7.35-$7.45 from prior guidance of $7.14-$7.27 vs. $7.23.
-Raised GAAP diluted EPS guidance range to $5.60 to $5.70 from $5.16 to $5.29
-Raised cash flow from operations guidance range to $12.75 billion to $13.25 billion from $11.0 billion to $11.5 billion
⚡️🇺🇸#IMGN #отчетность
ImmunoGen Q3 GAAP
-EPS of -$0.13 beats by $0.06.
-Revenue of $18.19M (+37.0% Y/Y) beats by $2.96M.
The company has updated its financial guidance for 2020 as follows:
-revenues between $60 million and $65 million vs. $67.37M;
-operating expenses between $160 million and $165 million;
-cash and cash equivalents at December 31, 2020 to be between $245 million and $250 million.
ImmunoGen Q3 GAAP
-EPS of -$0.13 beats by $0.06.
-Revenue of $18.19M (+37.0% Y/Y) beats by $2.96M.
The company has updated its financial guidance for 2020 as follows:
-revenues between $60 million and $65 million vs. $67.37M;
-operating expenses between $160 million and $165 million;
-cash and cash equivalents at December 31, 2020 to be between $245 million and $250 million.
🇷🇺#авиа #отставкиназначения #UNAC
Глава ОАК Юрий Слюсарь назначен гендиректором "Сухого", будет совмещать две должности - РИА
Глава ОАК Юрий Слюсарь назначен гендиректором "Сухого", будет совмещать две должности - РИА
⚡️💥🇺🇸#AZN
AstraZeneca's получила ОК на использование препарата Brilinta в США
AstraZeneca's получила ОК на использование препарата Brilinta в США
⚡️🇺🇸#HSY #отчетность
Hershey Q3 Non-GAAP
-EPS of $1.86 beats by $0.14; GAAP EPS of $2.14 beats by $0.42.
-Revenue of $2.22B (+4.2% Y/Y) beats by $60M.
-Organic sales growth of 3.8%, above consensus of 2.5%.
Hershey Q3 Non-GAAP
-EPS of $1.86 beats by $0.14; GAAP EPS of $2.14 beats by $0.42.
-Revenue of $2.22B (+4.2% Y/Y) beats by $60M.
-Organic sales growth of 3.8%, above consensus of 2.5%.
⚡️🇺🇸#COTY #отчетность
Coty FQ1 Non-GAAP
-EPS of -$0.02; GAAP EPS of $0.13 beats by $0.35.
-Revenue of $1.12B (-20.6% Y/Y) beats by $40M.
-Gross margin rate of 61.8% vs. consensus of 61.4%.
Coty FQ1 Non-GAAP
-EPS of -$0.02; GAAP EPS of $0.13 beats by $0.35.
-Revenue of $1.12B (-20.6% Y/Y) beats by $40M.
-Gross margin rate of 61.8% vs. consensus of 61.4%.
Forwarded from MarketTwits
❗️🇺🇸#BIIB
вчера у Biogen был оч хороший день - ожидается, что регулятор одобрит препарат aducanumab от болезни Альцгеймера в пятницу
The FDA's Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Friday, November 6, to review and discuss Biogen's marketing application seeking approval of aducanumab for the treatment of Alzheimer's disease (AD).
(а прикинте, если не одобрит ✊)
вчера у Biogen был оч хороший день - ожидается, что регулятор одобрит препарат aducanumab от болезни Альцгеймера в пятницу
The FDA's Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Friday, November 6, to review and discuss Biogen's marketing application seeking approval of aducanumab for the treatment of Alzheimer's disease (AD).
(а прикинте, если не одобрит ✊)
⚡️🇺🇸#MYL #отчетность
Mylan Q3 Non-GAAP
-EPS of $1.31 beats by $0.15; GAAP EPS of $0.36 misses by $0.12.
-Revenue of $2.97B (+0.3% Y/Y) misses by $30M.
-Non-GAAP gross margin of 55% vs. consensus of 53.1%.
Mylan Q3 Non-GAAP
-EPS of $1.31 beats by $0.15; GAAP EPS of $0.36 misses by $0.12.
-Revenue of $2.97B (+0.3% Y/Y) misses by $30M.
-Non-GAAP gross margin of 55% vs. consensus of 53.1%.
⚡️🇺🇸#MAR #отчетность
Marriott Q3 Non-GAAP
-EPS of $0.06 beats by $0.14; GAAP EPS of $0.31 beats by $0.45.
-Revenue of $2.25B (-57.4% Y/Y) misses by $40M.
-Comp. system RevPAR of -65.9% vs. consensus of -65.2%.
-Adjusted EBITDA of $327M vs. consensus of $239.1M.
Marriott Q3 Non-GAAP
-EPS of $0.06 beats by $0.14; GAAP EPS of $0.31 beats by $0.45.
-Revenue of $2.25B (-57.4% Y/Y) misses by $40M.
-Comp. system RevPAR of -65.9% vs. consensus of -65.2%.
-Adjusted EBITDA of $327M vs. consensus of $239.1M.
⚡️🇷🇺#MSNG #отчетность
ЧИСТАЯ ПРИБЫЛЬ МОСЭНЕРГО ПО МСФО ЗА 9 МЕСЯЦЕВ СОСТАВИЛА 5,344 МЛРД РУБ ПРОТИВ 12,624 МЛРД РУБ ГОДОМ РАНЕЕ – КОМПАНИЯ - ПРАЙМ
МОСЭНЕРГО ЗА 9 МЕСЯЦЕВ СОКРАТИЛО EBITDA ПО МСФО НА 18,9% ДО 21,26 МЛРД РУБ - КОМПАНИЯ
ЧИСТАЯ ПРИБЫЛЬ МОСЭНЕРГО ПО МСФО ЗА 9 МЕСЯЦЕВ СОСТАВИЛА 5,344 МЛРД РУБ ПРОТИВ 12,624 МЛРД РУБ ГОДОМ РАНЕЕ – КОМПАНИЯ - ПРАЙМ
МОСЭНЕРГО ЗА 9 МЕСЯЦЕВ СОКРАТИЛО EBITDA ПО МСФО НА 18,9% ДО 21,26 МЛРД РУБ - КОМПАНИЯ
⚡️🇺🇸#VIAC #отчетность
ViacomCBS Q3 Non-GAAP
-EPS of $0.91 beats by $0.11; GAAP EPS of $0.99 beats by $0.19.
-Revenue of $6.11B (-8.8% Y/Y) beats by $150M.
-Operating income of $959M vs. consensus of $924M.
ViacomCBS Q3 Non-GAAP
-EPS of $0.91 beats by $0.11; GAAP EPS of $0.99 beats by $0.19.
-Revenue of $6.11B (-8.8% Y/Y) beats by $150M.
-Operating income of $959M vs. consensus of $924M.
⚠️🇺🇸#акции #сша #дивергенция #наблюдение #smartmoney #макро #warning #выборы
дивергенция между индексом финпотоков "умных денег" и индексом DOW
👉 дивергенция между индексом "умных денег" и SP500
дивергенция между индексом финпотоков "умных денег" и индексом DOW
👉 дивергенция между индексом "умных денег" и SP500